Clinical, treatment and prognosis in children with FSGS: A 5 year retrospective study

Ling Chen; Liu Xiaorong; Shen Ying; Chen Zhi; Fan Jianfeng; Jiang Yeping

doi:10.4172/2161-0959.C1.025

Clinical, treatment and prognosis in children with FSGS: A 5 year retrospective study

6^th Annual conference on Clinical & Pediatric Nephrology

May 09-10, 2016 New Orleans, USA

Ling Chen, Liu Xiaorong, Shen Ying, Chen Zhi, Fan Jianfeng and Jiang Yeping

Capital Medical University, China

Posters & Accepted Abstracts: J Nephrol Ther

Abstract :

Aim: To investigate the clinical and pathological characteristics in children with Focal segmental glomerular sclerosis and to evaluate the associated factors of clinical outcome and the efficacy of treatment. Methods: The clinical and pathological characteristics, the associated factors of clinical outcome and the efficacy of treatment were analyzed retrospectively in 62 children with FSGS from June 2007 to June 2012. Results & Conclusion: Based on clinical and pathological classification: 49 patients with edema and proteinuria (79.0%), 25 patients with hematuria (40.3%), 15 patients with hypertension (24.2%), 7 patients with acute renal injury (9.6%). Renal pathology revealed 45 patients with not otherwise specified type (NOS) (72.6%), 9 with glomerular tip lesion type (Tips) (14.5%), 8 with cellular type (Cellular) (12.9%). The complete remission rate of NOS was 28.9% (13/45) and the partial remission rate was 33.3% (15/45) and no remission rate was 37.8% (17/35). The complete remission rate of Tips was 45.6% (5/9) and the partial remission rate was 33.3% (3/9) and no remission rate was 11.1% (1/9). The complete remission rate of Cellular was 25% (2/8) and no remission rate was 75% (6/8). The prognosis correlated with the pathological characteristics and the therapy plan (r=0.142, 0.327, respectively, P<0.05). Of these FSGS patients, 12% patient experienced remission after Prednisone and cyclophosphamide pulse therapy (P+CTX) and the total efficacy was 40%, which was statistically lower than that of children who received Prednisone and Cyclosporin A (P+CsA) or Prednisone and Tacrolimus (P+TAC) (37.5% and 75% or 42.9% and 71.4%, respectively). No significant statistical difference in prognosis was found in patients with P+CsA or P+TAC group (p>0.05). High blood pressure and persistent large proteinuria do harmful for the prognosis (P<0.05) rather than age, gender, pathological type and treatment plan.